Compare ASRV & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | RNTX |
|---|---|---|
| Founded | 1983 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 65.3M |
| IPO Year | 1994 | 2017 |
| Metric | ASRV | RNTX |
|---|---|---|
| Price | $4.74 | $0.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 11.6K | ★ 348.7K |
| Earning Date | 04-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | 44.16 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.69 |
| 52 Week High | $5.38 | $2.18 |
| Indicator | ASRV | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 50.94 |
| Support Level | $3.62 | $0.71 |
| Resistance Level | $5.09 | $0.85 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 42.19 | 61.46 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.